BLCO · Bausch & Lomb Corp
$16.57
+0.22 (+1.35%)
At close · Aug 7
Market Cap
$5.84B
Shares
357.17M
Bausch & Lomb Corp Earnings Call Transcripts
Every quarterly earnings call for Bausch & Lomb Corp (BLCO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼0.7%
$942.00M
−$18.00M
'22 Q3
22-11-02
▼0.5%
$996.00M
−$1.00M
'22 Q4
23-02-22
▲4.7%
$931.00M
−$90.00M
'23 Q1
23-05-03
▲10%
$1.03B
−$32.00M
'23 Q2
23-08-02
▲6.9%
$1.01B
−$84.00M
'23 Q3
23-11-01
▲17.8%
$1.17B
−$54.00M
'23 Q4
24-02-21
▲18%
$1.10B
−$167.00M
'24 Q1
24-05-01
▲17.5%
$1.22B
−$151.00M
'24 Q2
24-07-31
▲18.8%
$1.20B
$4.00M
'24 Q3
24-10-30
▲9.1%
$1.28B
−$3.00M
'24 Q4
25-02-19
▲3.5%
$1.14B
−$212.00M
'25 Q1
25-04-30
▲5.1%
$1.28B
−$62.00M
'25 Q2
25-07-30
▲7.1%
$1.28B
−$28.00M
'25 Q3
25-10-29
▲9.8%
$1.41B
−$58.00M
'25 Q4
26-02-18
▲9.4%
$1.24B
−$71.00M
'26 Q1
26-04-29
LATEST
▲9.1%
$1.39B
−$14.00M
'26 Q2
26-07-29
Earnings call
FY26 · Q2
2026-07-29
Bausch & Lomb Corp Q2 FY2026 Earnings Call
Confident tone
Pharmaceuticals (MIBO/Miebo and Zydra)
Cash flow and balance sheet / leverage
Pipeline and R&D milestones
Revenue
$1.39B
▲ 9.1% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Bausch & Lomb Corp Q1 FY2026 Earnings Call
Confident tone
Pharmaceuticals strength
Pipeline and R&D progress
Vision Care and contact lenses
Revenue
$1.24B
▲ 9.4% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-18
Bausch & Lomb Corp Q4 FY2025 Earnings Call
Confident tone
Dry eye portfolio (Miebo, Blink)
Consumer franchise (LUMIFY, PreserVision)
Pipeline and R&D
Revenue
$1.41B*
▲ 9.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Bausch & Lomb Corp Q3 FY2025 Earnings Call
Positive tone
Pharmaceuticals / Miebo performance
Investor Day and 3-year plan
Surgical / IOL recovery
Revenue
$1.28B
▲ 7.1% YoY Diluted EPS
$-0.08
▼ 900% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Bausch & Lomb Corp Q2 FY2025 Earnings Call
Positive tone
Dry eye portfolio growth
enVista IOL recall recovery
Consumer / LUMIFY performance
Revenue
$1.28B
▲ 5.1% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Bausch & Lomb Corp Q1 FY2025 Earnings Call
Positive tone
enVista IOL voluntary recall and recovery
2025 guidance and outlook
Vision Care / contact lens growth
Revenue
$1.14B
▲ 3.5% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Bausch & Lomb Corp Q4 FY2024 Earnings Call
Revenue
$1.28B*
▲ 9.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Bausch & Lomb Corp Q3 FY2024 Earnings Call
Confident tone
Pharmaceutical segment (Miebo, Xiidra)
Execution and revenue growth momentum
Product launch cycle and launches
Revenue
$1.20B
▲ 18.8% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Bausch & Lomb Corp Q2 FY2024 Earnings Call
Confident tone
Pharmaceuticals / MIEBO
Innovation and Product Launches
Constant Currency Revenue Growth
Revenue
$1.22B
▲ 17.5% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Bausch & Lomb Corp Q1 FY2024 Earnings Call
Confident tone
Innovation pipeline and product launches
Miebo (dry eye) launch and reimbursement coverage
Revenue growth and segment performance
Revenue
$1.10B
▲ 18% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
Bausch & Lomb Corp Q4 FY2023 Earnings Call
Confident tone
Dry Eye Franchise (Miebo and Xiidra)
2024 Product Launches
Margin Expansion Guidance
Revenue
$1.17B*
▲ 17.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Bausch & Lomb Corp Q3 FY2023 Earnings Call
Revenue
$1.01B
▲ 6.9% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Bausch & Lomb Corp Q2 FY2023 Earnings Call
Revenue
$1.03B
▲ 10% YoY Diluted EPS
$-0.09
▼ 1000% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Bausch & Lomb Corp Q1 FY2023 Earnings Call
Revenue
$931.00M
▲ 4.7% YoY Diluted EPS
$-0.26
▼ 533.3% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Bausch & Lomb Corp Q4 FY2022 Earnings Call
Revenue
$996.00M*
▼ 0.5% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Bausch & Lomb Corp Q3 FY2022 Earnings Call
Revenue
$942.00M
▼ 0.7% YoY Diluted EPS
$-0.05
▼ 129.4% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Bausch & Lomb Corp Q2 FY2022 Earnings Call
Revenue
$941.00M
▲ 0.7% YoY Diluted EPS
$0.01
▼ 92.3% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-06-08
Bausch & Lomb Corp Q1 FY2022 Earnings Call
Revenue
$889.00M
▲ 0.9% YoY Diluted EPS
$0.06
▼ 25% YoY
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–18 of 18 earnings calls
Key facts
CIK
1860742
CUSIP
071705107
13F (30d)
20 filings
20 filers
Visit website
Investor relations